A substituted 8,9-dihydropyrimido[5,4-b]indolizine compound, pharmaceutical composition and use thereof

Resistance and toxic side effects of EGFR tyrosine kinase inhibitors in the treatment of non-small cell lung cancer by developing a new substituted 8,9-dihydropyrimidino[5,4-b]inazine compound Problem, effective inhibition and low toxic therapeutic effects on EGFR mutant cancer cells were achieved.

CN115785107BActive Publication Date: 2024-11-12南京雷正医药科技有限公司
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211613435.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-12-15
Publication Date
2024-11-12
Estimated Expiration
2042-12-15

AI Technical Summary

Technical Problem

Existing EGFR tyrosine kinase inhibitors are prone to drug resistance in the treatment of non-small cell lung cancer, especially drug resistance mutant proteins after EGFR gene mutations are not effective for treatment and have toxic side effects.

Method used

Develop a new substituted 8,9-dihydropyrimidine[5,4-b]inazine compound, as an EGFR inhibitor, has excellent inhibitory activity and low toxic side effects, and is used to overcome drug resistance and toxic side effects. question. The compound can be used as a pharmaceutical composition in combination with other drugs to improve therapeutic effects.

Benefits of technology

This compound showed excellent EGFR inhibitory activity, had a strong growth inhibitory effect on EGFR mutant cancer cells, had almost no side effects, and had good development prospects and therapeutic effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115785107B_ABST
    Figure CN115785107B_ABST
Patent Text Reader

Abstract

The present invention discloses a substituted 8,9-dihydropyrimido[5,4-b]indolizine compound, a pharmaceutical composition and a use thereof, and belongs to the field of chemical medicine. The structure of the substituted 8,9-dihydropyrimido[5,4-b]indolizine compound and a pharmaceutically acceptable salt thereof of the present invention is shown in formula (I), and can be used as an epidermal growth factor receptor (EGFR) inhibitor, and can be used to prevent and / or treat cancer based on the EGFR inhibitory effect. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of chemical medicine, and relates to a substituted 8,9-dihydropyrimido[5,4-b]indolizine compound, a pharmaceutical composition and use thereof. Background Art

[0002] Lung cancer is the number one killer among tumors, and about 85% of them are advanced non-small cell lung cancer. For a long time, chemotherapy with platinum-based drugs was the only option for treating advanced non-small cell lung cancer (NSCLC). This treatment method has increased the patient's overall survival (OS) to a certain extent, but it only has a 20% response rate and a median survival of 8-10 months. After a certain period of chemotherapy, cancer cells develop drug resistance due to new mutations. Among patients with lung adenocarcinoma, approximately 15% of Caucasians and 30-50% of East Asians have EGFR gene mutations. For those East Asians with no history of smoking, this proportion is as high as 50-60%.

[0003] Epidermal growth factor receptor (EGFR) is a transmembrane protein tyrosine kinase of the ErbB receptor family. When it binds to a growth factor ligand (e.g., epidermal growth factor (EGF), the receptor can homodimerize with an attached EGFR molecule, or heterodimerize with another family member (e.g., ErbB2 (HER2), ErbB3 (HER3), or ErbB4 (HER4). The homodimerization and / or heterodimerization of ErbB receptors leads to the phosphorylation of key tyrosine residues in cells and the stimulation of many intracellular signal transduction pathways involved in cell proliferation and survival. Dysregulation of ErbB family signal transduction promotes proliferation, invasion, metastasis, angiogenesis, and survival of tumor cells, and is closely related to human cancers such as lung cancer, head and neck cancer, colon cancer, and breast cancer.

[0004] EGFR tyrosine kinase inhibitors (TKIs) have been developed as targeted drugs for the treatment of non-small cell lung cancer. Early small molecule EGFR tyrosine kinase inhibitors (EGFR-TKIs) such as gefitinib and erlotinib were used to treat all NSCLC patients who had previously received chemotherapy when they were first introduced. Therefore, a series of new EGFR TKIs such as afatinib and dacomitinib have made great progress on this basis. However, cancers acquire resistance to gefitinib and erlotinib 6-12 months after the start of treatment, and the treatment effect becomes poor.

[0005] Therefore, this acquired drug resistance becomes a serious problem in the treatment of non-small cell lung cancer with highly susceptible mutant EGFR. It has been shown that about 50% of acquired drug resistance is due to the appearance of drug-resistant mutant EGFR proteins EGFR (d746-750 / T790M) or EGFR (T790M / L858R), which have a second mutation in the EGFR gene, causing the 790th amino acid to change from threonine to methionine. The development of therapeutic agents that are effective against non-small cell lung cancer with this drug-resistant mutant EGFR is an important task. Summary of the invention

[0006] The present inventors have discovered a new substituted 8,9-dihydropyrimido[5,4-b]indolizine compound in the process of studying EGFR inhibitors, which has excellent inhibitory activity against mutant EGFR and lower toxic side effects. It is expected that this type of inhibitor will have good therapeutic effects, is expected to overcome the problems of drug resistance and toxic side effects, and has good development prospects.

[0007] The present invention provides a substituted 8,9-dihydropyrimido[5,4-b]indolizine compound or a pharmaceutically acceptable salt thereof, a pharmaceutical composition and use thereof. The compound can be used as an EGFR inhibitor and has better pharmacodynamics and higher metabolic stability.

[0008] In one aspect, the present invention provides a compound having a structure represented by general formula (I) or a pharmaceutically acceptable salt thereof:

[0009]

[0010] In the formula, R 1 Selected from:

[0011] Among them, R 2 is selected from H, D, F, Cl, Br; R 3 , R 4 are independently selected from H or D; and R 2 , R 3 , R 4 Not H at the same time.

[0012] In one embodiment of the present invention, the compound is selected from:

[0013]

[0014] In one embodiment of the present invention, the pharmaceutically acceptable salt is an inorganic salt or an organic salt. The inorganic salt includes hydrochloride, hydrobromide, hydroiodide, perchlorate, sulfate, bisulfate, nitrate, phosphate, and acid phosphate; the organic salt is selected from formates, acetates, trifluoroacetates, propionates, pyruvates, glycolates, oxalates, malonates, succinates, glutarates, fumarates, maleates, lactates, malates, citrates, tartrates, methanesulfonates, ethanesulfonates, benzenesulfonates, salicylates, p-toluenesulfonates, and ascorbates.

[0015] The present invention also provides a pharmaceutical composition comprising the compound having a structure represented by the above general formula (I) or a pharmaceutically acceptable salt thereof.

[0016] In one embodiment of the present invention, the pharmaceutical composition further comprises: a pharmaceutically acceptable carrier, excipient or diluent.

[0017] In one embodiment of the present invention, the pharmaceutically acceptable carrier includes: microspheres, nanoparticles and liposomes.

[0018] When preparing a pharmaceutical composition, the compound of the general formula (I) of the present invention or a pharmaceutically acceptable salt thereof is usually mixed with a pharmaceutically acceptable carrier, excipient or diluent. In a unit dosage form (e.g., a tablet or capsule), the content of the compound of the general formula (I) or a pharmaceutically acceptable salt thereof may be 0.01-1000 mg, such as 0.05-800 mg, 0.1-500 mg, 0.01-300 mg, 0.01-200 mg, 0.05-150 mg, 0.05-50 mg, etc.

[0019] The composition of the present invention can be prepared into conventional pharmaceutical preparations according to conventional preparation methods, such as tablets, pills, capsules, powders, granules, emulsions, suspensions, dispersions, solutions, tinctures, syrups, ointments, drops, suppositories, inhalants, sprays, etc.

[0020] In certain embodiments, the compounds of the present invention or their pharmaceutically acceptable salts can be formulated into solid preparations for oral administration, including, but not limited to, capsules, tablets, pills, powders, granules, etc. In these solid dosage forms, the compounds of formula (I) of the present invention or their pharmaceutically acceptable salts are mixed as active ingredients with at least one conventional inert excipient (or carrier), for example, with sodium citrate or dicalcium phosphate, or with one or more selected from the following ingredients:

[0021] (1) Fillers or solubilizers, such as starch, lactose, sucrose, glucose, mannitol and silicic acid;

[0022] (2) Binders, for example, hydroxymethyl cellulose, alginate, gelatin, polyvinyl pyrrolidone, sucrose, gum arabic, etc.;

[0023] (3) humectants, such as glycerin;

[0024] (4) disintegrating agents, such as agar, calcium carbonate, potato starch or tapioca starch, alginic acid, certain silicates and sodium carbonate;

[0025] (5) Buffering solvents, such as paraffin;

[0026] (6) Absorption accelerators, such as quaternary ammonium compounds;

[0027] (7) Wetting agents, such as cetyl alcohol and glyceryl monostearate;

[0028] (8) Adsorbents, such as kaolin;

[0029] (9) Lubricants, for example, talc, calcium stearate, solid polyethylene glycol, sodium lauryl sulfate, etc., or mixtures thereof. Capsules, tablets, and pills may also contain buffers.

[0030] In certain embodiments, the solid dosage forms such as tablets, sugar pills, capsules, pills and granules can be coated or microencapsulated with coating and shell materials such as enteric coatings and other materials known in the art. They can contain opacifiers, and the release of the active ingredient in such compositions can be delayed in a certain part of the digestive tract. Examples of embedding components that can be used are polymeric substances and waxes. If necessary, the active ingredient can also be formed into microcapsules with one or more of the above-mentioned excipients.

[0031] In certain embodiments, the compounds of the present invention or their pharmaceutically acceptable salts can be formulated into liquid dosage forms for oral administration, including, but not limited to, pharmaceutically acceptable emulsions, solutions, suspensions, syrups, tinctures, etc. In addition to the active ingredient, the compound of formula (I) or its pharmaceutically acceptable salt, the liquid dosage form may contain inert diluents conventionally used in the art, such as water and other solvents, solubilizers and emulsifiers, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butylene glycol, dimethylformamide, and oils, in particular cottonseed oil, peanut oil, corn oil, olive oil, castor oil, sesame oil, etc. or mixtures of these substances, etc. In addition to these inert diluents, the liquid dosage form of the present invention may also include conventional adjuvants, such as wetting agents, emulsifiers and suspending agents, sweeteners, flavoring agents and spices, etc.

[0032] The suspending agent includes, for example, ethoxylated stearyl alcohol, polyoxyethylene sorbitol, and sorbitan, microcrystalline cellulose, agar, etc. or a mixture of these substances.

[0033] In certain embodiments, the compounds of the present invention and their pharmaceutically acceptable salts can be formulated into dosage forms for parenteral injection, including, but not limited to, physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions and dispersions. Suitable carriers, diluents, solvents, excipients include water, ethanol, polyols and suitable mixtures thereof.

[0034] In certain embodiments, the compounds of the present invention or their pharmaceutically acceptable salts can be formulated into dosage forms for topical administration, including ointments, powders, suppositories, drops, sprays, inhalants, etc. The compounds of the present invention of general formula (I) or their pharmaceutically acceptable salts as active ingredients are mixed with physiologically acceptable carriers and optional preservatives, buffers, and propellants that may be required under sterile conditions.

[0035] The present invention also provides the use of the compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating diseases mediated by EGFR activated or drug-resistant mutants in mammals, especially humans.

[0036] The present invention also provides the use of the compound having the structure represented by the above general formula (I) or a pharmaceutically acceptable salt thereof in the preparation of anticancer drugs.

[0037] In certain embodiments, the cancer comprises lung cancer, breast cancer, kidney cancer, prostate cancer, pancreatic cancer, epidermal cancer.

[0038] The compound of the present invention or its pharmaceutically acceptable salt can be administered alone or in combination with other pharmaceutically acceptable therapeutic agents, especially in combination with other anti-tumor drugs. The therapeutic agent includes but is not limited to: anti-tumor drugs acting on the chemical structure of DNA, such as cisplatin, anti-tumor drugs affecting nucleotide synthesis such as methotrexate, 5-fluorouracil, etc., anti-tumor drugs affecting nucleic acid transcription such as doxorubicin, epirubicin, aclarubicin, etc., anti-tumor drugs acting on microscopic protein synthesis such as paclitaxel, vinorelbine, etc., aromatase inhibitors such as aminoglutethimide, letrozole, arinide, etc., cell signaling pathway inhibitors such as epidermal growth factor receptor inhibitors imatinib (Imatinib), gefitinib (Gefitinib), erlotinib (Erlotinib), etc. The components to be combined can be administered simultaneously or sequentially, in the form of a single preparation or in the form of different preparations. The combination includes not only a combination of one or other active agents of the compound of the present invention, but also a combination of two or more other active agents of the compound of the present invention.

[0039] In another aspect, the present invention also provides a method for preparing a compound of general formula (I), the method comprising:

[0040]

[0041] At 0°C, a dichloromethane solution of compound 2 was added to a dichloromethane solution containing intermediate 1 and N,N-diisopropylethylamine, and the mixture was stirred at room temperature for reaction. After the reaction was completed, the mixture was washed with water, dried, concentrated, and the crude product was separated by reverse phase preparative separation to obtain the target compound. 4 The definitions of are the same as those in the general formula (I).

[0042] Effects of the Invention

[0043] According to the present invention, there is provided a novel compound represented by the above formula (I) or a salt thereof which is useful as an EGFR inhibitor.

[0044] The compound or salt thereof of the present invention has excellent EGFR inhibitory activity and cancer cell line growth inhibition effect. In addition, due to the excellent selectivity for EGFR, the compound or salt thereof of the present invention has almost no side effects. Therefore, the compound designed by the present invention has a good development and application prospect. DETAILED DESCRIPTION

[0045] The technical solution of the present invention will be described in detail below in conjunction with embodiments.

[0046] As used herein, the term "disease" refers to any condition or disorder that damages or interferes with the normal function of a cell, organ, or tissue.

[0047] As used herein, the term "inhibitor" refers to a compound or agent that has the ability to inhibit the biological function of a targeted protein or polypeptide, for example, by inhibiting the activity or expression of the protein or polypeptide.

[0048] As used herein, the term "anti-neoplastic agent" refers to any agent useful in the treatment of neoplastic disorders.

[0049] As used herein, the term "pharmaceutically acceptable" refers to a component that is suitable for contact with the tissues of humans and other mammals without excessive toxicity, irritation, allergic response, etc., within a reasonable medical range and has a reasonable benefit / risk ratio. "Pharmaceutically acceptable salt" refers to any non-toxic salt that, after administration to a recipient, can directly or indirectly provide a compound of the present invention or a prodrug of the compound.

[0050] As used herein, the term "effective amount" or "effective therapeutic amount" refers to an amount of a compound or pharmaceutical composition described herein that is sufficient to achieve the intended application, including, but not limited to, treating a disease. In some embodiments, the amount is detected to be effective for killing or inhibiting cancer cell growth or spread; the size or number of tumors; or the severity level, stage and progression of cancer. The effective therapeutic amount may vary depending on the intended application, such as in vitro or in vivo, the condition and severity of the disease, the age, weight, or mode of administration of the subject, etc. The term also applies to doses that will induce a specific response in target cells, such as reducing cell migration. The specific dose will depend on, for example, the specific compound selected, the subject species and their age / existing health condition or health condition risk, the route of administration, the severity of the disease, administration in combination with other agents, the time of administration, the tissue to which it is administered, and the drug delivery device, etc.

[0051] "Administration" or "administering" a subject compound in the context of the present invention means providing the subject in need of treatment with a compound of the present invention.

[0052] The compounds of the present invention may contain one or more asymmetric centers and therefore occur as racemates and racemic mixtures, single enantiomers, individual diastereomers and diastereomeric mixtures. All such isomeric forms of these compounds are expressly included in the present invention. The compounds of the present invention may also exhibit multiple tautomeric forms, in which case, the present invention expressly includes all tautomeric forms of the compounds described herein. All such isomeric forms of such compounds are included in the present invention. All crystalline forms of the compounds described herein are expressly included in the present invention.

[0053] The following examples are used to illustrate but not to limit the synthesis of compounds of formula (I). All temperatures are in degrees Celsius. Unless otherwise stated, all evaporations were carried out under reduced pressure. Unless otherwise stated, reagents were purchased from commercial suppliers and used without further purification. The structures of the final products, intermediates and raw materials were confirmed by standard analytical methods, such as elemental analysis, spectral feature analysis, such as MS, NMR. The abbreviations used are conventional abbreviations in the art, and some intermediates were purchased from Yancheng Zhengchi Biotechnology Co., Ltd.

[0054] The following intermediate substances are involved in the specific embodiments, and can be synthesized by referring to the following route process:

[0055] Preparation of (S)-6-methyl-5-(quinolin-3-yl)-8,9-dihydropyrimido[5,4-b]indolizine-4,8-diamine (Intermediate 1)

[0056]

[0057] Step 1: Preparation of tert-butyl (S)-(l-(4-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)pent-4-en-2-yl)carbamate (Intermediate c)

[0058] Dissolve (S)-(l-hydroxypent-4-en-2-yl)carbamic acid tert-butyl ester (3g, 14.9mmol) and 4-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine (4.16g, 14.9mmol) in DME (50mL). Add triphenylphosphine (4.69g, 17.9mmol) and diisopropyl azodicarboxylate (3.61g, 17.9mmol) in turn under ice bath. Stir the reaction solution under ice bath for 30 minutes and then at room temperature for 1 hour. After the reaction is completed, concentrate, dilute with ethyl acetate, wash the organic phase with water, and dry over anhydrous sodium sulfate. Concentrate under reduced pressure. The obtained crude product was purified by silica gel column chromatography to obtain (S)-tert-butyl (1-(4-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)pent-4-en-2-yl)carbamate (4.5 g, yield: 65%) as a light yellow solid. ESI-MS m / z: 463, 465 [M+H]+.

[0059] Step 2: Preparation of tert-butyl (S)-(l-(4-amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)pent-4-en-2-yl)carbamate (intermediate d)

[0060] Dissolve (S)-(l-(4-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)pent-4-ene-2-yl)carbamic acid tert-butyl ester (4.5 g, 9.74 mmol) in DME (50 mL), add concentrated aqueous ammonia (20 mL), and heat the reaction solution to 100°C in an autoclave and stir for 8 hours. After the reaction is completed, cool to room temperature, add water (100 mL), and stir at room temperature for 4 hours. Solid precipitates, is filtered, washed with water, and dried to obtain (S)-(l-(4-amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)pent-4-ene-2-yl)carbamic acid tert-butyl ester (4 g, yield: 93%), a light yellow solid. ESI-MS m / z: 444[M+H]+.

[0061] Step 3: Preparation of tert-butyl (S)-(l-(4-amino-5-(quinolin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)pent-4-en-2-yl)carbamate (Intermediate f)

[0062] Dissolve (S)-tert-butyl (l-(4-amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)pent-4-en-2-yl)carbamate (4g, 9.0mmol), 3-quinolineboronic acid (1.87g, 10.8mmol), sodium carbonate (1.9g, 18mmol), tetrakis(triphenylphosphine)palladium (1.04g, 0.9mmol) in DME (40mL) and water (40mL), heat to 100°C and stir for 6 hours under nitrogen protection. After the reaction is completed, cool to room temperature, filter, and extract with ethyl acetate. Dry the organic phase over anhydrous sodium sulfate and concentrate under reduced pressure. The obtained crude product was purified by silica gel column chromatography to obtain (S)-tert-butyl (l-(4-amino-5-(quinolin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)pent-4-en-2-yl)carbamate (3 g, yield: 75%) as a light yellow solid. ESI-MS m / z: 445 [M+H]+.

[0063] Step 4: Preparation of tert-butyl (S)-(l-(4-amino-6-bromo-5-(quinolin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)pent-4-en-2-yl)carbamate (Intermediate g)

[0064] Dissolve (S)-tert-butyl (l-(4-amino-5-(quinolin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)pent-4-en-2-yl)carbamate (3 g, 6.75 mmol) in DMF (50 mL), cool to -15°C, add NBS (1.2 g, 6.75 mmol) in batches, and then stir at -15°C for 1 hour. After the reaction is completed, add 10% sodium thiosulfate aqueous solution (50 mL), extract with ethyl acetate, wash the organic phase with saturated sodium chloride, and dry over anhydrous sodium sulfate. Concentrate under reduced pressure. The obtained crude product was purified by silica gel column chromatography to obtain (S)-tert-butyl (l-(4-amino-6-bromo-5-(quinolin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)pent-4-en-2-yl)carbamate (2.8 g, yield: 79%) as a light brown solid. ESI-MS m / z: 523, 525 [M+H]+.

[0065] Step 5: Preparation of tert-butyl (S)-(4-amino-6-methyl-5-(quinolin-3-yl)-8,9-dihydropyrimido[5,4-b]indolizine-8-yl)carbamate (Intermediate h)

[0066] Dissolve (S)-tert-butyl (l-(4-amino-6-bromo-5-(quinolin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)pent-4-en-2-yl)carbamate (2.8 g, 5.35 mmol) in THF (50 mL), add 4N sodium hydroxide aqueous solution (5 mL) and tetrakis(triphenylphosphine)palladium (612 mg, 0.53 mmol), heat to 80 ° C under nitrogen protection, and stir overnight. After the reaction is completed, cool to room temperature, filter, and extract with ethyl acetate. The organic phase is dried over anhydrous sodium sulfate. Concentrate under reduced pressure. The obtained crude product is purified by reverse phase preparation to obtain tert-butyl (S)-(4-amino-6-methyl-5-(quinolin-3-yl)-8,9-dihydropyrimido[5,4-b]indolizine-8-yl)carbamate (1.5 g, yield: 63%) as a yellow solid. ESI-MS m / z:443[M+H]+.

[0067] Step 6: Preparation of (S)-6-methyl-5-(quinolin-3-yl)-8,9-dihydropyrimido[5,4-b]indolizine-4,8-diamine (Intermediate 1)

[0068] Dissolve (S)-(4-amino-6-methyl-5-(quinolin-3-yl)-8,9-dihydropyrimido[5,4-b]indolizine-8-yl)carbamic acid tert-butyl ester (1.5 g, 3.4 mmol) in 4M hydrochloric acid-dioxane (20 mL) and react at room temperature for 5 hours. After the reaction, concentrate under reduced pressure, adjust the pH to 8-9 with 2M sodium hydroxide aqueous solution, extract with ethyl acetate, dry the organic phase, and concentrate to obtain (S)-6-methyl-5-(quinolin-3-yl)-8,9-dihydropyrimido[5,4-b]indolizine-4,8-diamine (1 g, yield: 86%) as a light yellow solid. ESI-MS m / z: 343[M+H]+.

[0069] Example 1: (S)-N-(4-amino-6-methyl-5-(quinolin-3-yl)-8,9-dihydropyrimido[5,4-b]indolizine-8-yl)-3,3-dideuteroacrylamide

[0070]

[0071] (S)-6-methyl-5-(quinolin-3-yl)-8,9-dihydropyrimido[5,4-b]indolizine-4,8-diamine (Intermediate 1) (100 mg, 0.29 mmol) and triethylamine (35 mg, 0.35 mmol) were dissolved in dichloromethane (5 mL), 3,3-dideuteroacryloyl chloride (32 mg, 0.35 mmol) was slowly added at 0°C, and the mixture was reacted at 0°C for 1 hour. After the reaction was completed, the mixture was quenched with water, extracted with dichloromethane, and the organic phase was dried over anhydrous sodium sulfate and concentrated. The crude product was subjected to reverse phase HPLC to obtain (S)-N-(4-amino-6-methyl-5-(quinolin-3-yl)-8,9-dihydropyrimido[5,4-b]indolizine-8-yl)-3,3-dideuteroacrylamide (42 mg, yield: 36%) as a light yellow solid. ESI-MS m / z:399[M+H] + .

[0072] 1 H-NMR (400 MHz, DMSO-d 6 ): δ8.93(s,l H),8.45(d,J=7.2Hz,l H),8.40(s,l H),8.14(s,1H),8.10(d,J=8.6Hz,1H),8.06(d,J=8.4Hz,1H),7.82(t,J=7.6Hz,1H),7.68(t,J=7.1Hz,1H),6.26(dd,J=17.2,9.8Hz,1H),6 .16(dd,J=17.2,2.4Hz,1H),6.01-5.67(brs,2H),4.85-4.75(m,1H),4.26(dd=13.3,5.2Hz,1H),4.18(dd,J=13.3,5.2Hz,1H),1.53(s,3H).

[0073] Example 2: (S)-N-(4-amino-6-methyl-5-(quinolin-3-yl)-8,9-dihydropyrimido[5,4-b]indolizine-8-yl)-3,3,2-trideuteroacrylamide

[0074]

[0075] The compound of Example 2 was synthesized by referring to the method of Example 1, wherein 3,3,2-trideuterated acryloyl chloride was used instead of 3,3-dideuterated acryloyl chloride to obtain the target compound (28.2 mg) as a light yellow solid. ESI-MS m / z: 400 [M+H] + .

[0076] 1 H-NMR (400 MHz, DMSO-d 6): δ8.93(s,l H),8.45(d,J=7.1Hz,lH),8.40(s,lH),8.14(s,lH),8.10(d,J=8.6Hz,lH),8.06(d,J=8.1Hz,lH),7.82(t,J=7.6Hz,l H),7.68(t,J=7.1Hz,l H),6.26(dd,J=17.1,9.8Hz,l H),6.02(s,2H),4.85-4.75(m,l H),4.26(dd,J=13.2,5.1Hz,l H),4.18(dd,J=13.2,5.1Hz,l H),1.53(s,3H).

[0077] Example 3: (S)-N-(4-amino-6-methyl-5-(quinolin-3-yl)-8,9-dihydropyrimido[5,4-b]indolizine-8-yl)-2-fluoroacrylamide

[0078]

[0079] The compound of Example 3 was synthesized by referring to the method of Example 1, wherein 2-fluoroacryloyl chloride was used instead of 3,3-dideuteroacryloyl chloride to obtain the target compound (22.6 mg) as a light yellow solid.

[0080] ESI-MS m / z:415[M+H] +

[0081] 1 H-NMR (400 MHz, DMSO-d 6 ): δ8.86(s,l H),8.45(d,J=7.0Hz,lH),8.40(s,lH),8.14(s,lH),8.11(d,J=8.6Hz,lH),8.06(d,J=8.1Hz,lH),7.81(t,J=7.6Hz,l H),7.66(t,J=7.5Hz,l H),6.25(dd,J=17.1,9.8Hz,l H),6.03(s,2H),5.88-5.64(m,2H),4.87-4.79(m,l H),4.27-4.17(m,l H),1.54(s,3H).

[0082] Example 4: (S)-N-(4-amino-6-methyl-5-(quinolin-3-yl)-8,9-dihydropyrimido[5,4-b]indolizine-8-yl)-2-methylacrylamide

[0083]

[0084] The compound of Example 4 was synthesized by referring to the method of Example 1, wherein 2-methacryloyl chloride was used instead of 3,3-dideuteroacryloyl chloride to obtain the target compound (42.1 mg) as a light yellow solid. ESI-MS m / z: 411 [M+H] + .

[0085] 1 H-NMR (400 MHz, DMSO-d 6 ): δ8.88(s,l H),8.44(d,J=7.0Hz,lH),8.41(s,lH),8.14(s,lH),8.11(d,J=8.6Hz,lH),8.06(d,J=8.1Hz,lH),7.81(t,J=7.6Hz,l H),7.65(t,J=7.1Hz,l H),6.24(dd,J=17.1,9.8Hz,l H),6.03(s,2H),5.81(l H,dd,J=5.1,1.2Hz),5.60(l H,dd,J=9.8,2.7Hz),4.86-4.79(m,l H), 4.25 (dd, J=13.2, 5.1Hz, lH), 4.16 (dd, J=13.2, 5.1Hz, lH), 2.01 (s, 3H), 1.51 (s, 3H).

[0086] Example 5: (S)-N-(4-amino-6-methyl-5-(quinolin-3-yl)-8,9-dihydropyrimido[5,4-b]indolizine-8-yl)-2-trifluoromethylacrylamide

[0087]

[0088] The compound of Example 5 was synthesized by referring to the method of Example 1, wherein 2-trifluoromethylacryloyl chloride was used instead of 3,3-dideuterated acryloyl chloride to obtain the target compound (22.6 mg) as a light yellow solid. ESI-MS m / z: 465 [M+H] + .

[0089] 1 H-NMR (400 MHz, DMSO-d 6): δ8.93(s,l H),8.45(d,J=7.0Hz,lH),8.40(s,lH),8.14(s,lH),8.11(d,J=8.6Hz,lH),8.07(d,J=8.1Hz,lH),7.82(t,J=7.6Hz,l H),7.67(t,J=7.1Hz,l H),6.25(dd,J=17.1,9.8Hz,l H),6.03(s,2H),5.93-5.67(m,2H),4.92-4.84(m,l H),4.41-4.22(m,2H),1.61(s,3H).

[0090] Example 6: (S)-N-(4-amino-6-methyl-5-(quinolin-3-yl)-8,9-dihydropyrimido[5,4-b]indolizine-8-yl)-2-fluoro-3,3-dideuteroacrylamide

[0091]

[0092] The compound of Example 6 was synthesized by referring to the method of Example 1, wherein 2-fluoro-3,3-dideuteroacryloyl chloride was used instead of 3,3-dideuteroacryloyl chloride to obtain the target compound (15 mg) as a light yellow solid. ESI-MS m / z: 417 [M+H] + .

[0093] 1 H-NMR (400 MHz, DMSO-d 6 ): δ8.86(s,l H),8.45(d,J=7.0Hz,lH),8.40(s,lH),8.14(s,lH),8.11(d,J=8.6Hz,lH),8.06(d,J=8.1Hz,lH),7.86(t,J=7.6Hz,l H),7.66(t,J=7.5Hz,l H),6.25(dd,J=17.1,9.8Hz,l H),6.05(s,2H),4.89-4.79(m,l H),4.28-4.17(m,l H),1.58(s,3H).

[0094] Example 7: (S)-N-(4-amino-6-methyl-5-(quinolin-3-yl)-8,9-dihydropyrimido[5,4-b]indolizine-8-yl)-2-methyl-3,3-dideuteroacrylamide

[0095]

[0096] The compound of Example 7 was synthesized by referring to the method of Example 1, wherein 2-methyl-3,3-dideuteroacryloyl chloride was used instead of 3,3-dideuteroacryloyl chloride to obtain the target compound (30 mg) as a light yellow solid. ESI-MS m / z: 413 [M+H] + .

[0097] 1 H-NMR (400 MHz, DMSO-d 6 ): δ8.88(s,l H),8.44(d,J=7.0Hz,lH),8.41(s,lH),8.14(s,lH),8.11(d,J=8.6Hz,lH),8.06(d,J=8.1Hz,lH),7.81(t,J=7.6Hz,l H),7.65(t,J=7.1Hz,l H),6.24(dd,J=17.1,9.8Hz,l H),6.03(s,2H),4.86-4.79(m,l H),4.25(dd,J=13.2,5.1Hz,l H),4.16(dd,J=13.2,5.1Hz,l H),2.02(s,3H),1.54(s,3H).

[0098] Example 8: (S)-N-(4-amino-6-methyl-5-(quinolin-3-yl)-8,9-dihydropyrimido[5,4-b]indolizine-8-yl)-propargylamine

[0099]

[0100] (S)-6-methyl-5-(quinolin-3-yl)-8,9-dihydropyrimido[5,4-b]indolizine-4,8-diamine (Intermediate 1) (100 mg, 0.29 mmol) was dissolved in THF (2 mL), and propiolic acid (24 mg, 0.35 mmol), triethylamine (35 mg, 0.35 mmol) and T3P (222 mg, 0.35 mmol, w / w 50% in DMF) were added in sequence, and then reacted at room temperature for 3 h. After the reaction was completed, it was concentrated under reduced pressure. The crude product was subjected to reverse phase HPLC to obtain (S)-N-(4-amino-6-methyl-5-(quinolin-3-yl)-8,9-dihydropyrimido[5,4-b]indolizine-8-yl)-propargylamine (51 mg, yield: 44%) as a light yellow solid. ESI-MS m / z: 395 [M+H] + .

[0101] 1 H-NMR (400 MHz, DMSO-d 6): δ8.97(s,l H),8.45(d,J=7.1Hz,lH),8.40(s,lH),8.17(s,lH),8.13(d,J=8.6Hz,lH),8.06(d,J=8.1Hz,lH),7.83(t,J=7.6Hz,l H),7.67(t,J=7.1Hz,l H),6.22(dd,J=17.1,9.8Hz,l H),6.03(s,2H),4.88-4.71(m,l H),4.27(dd,J=13.2,5.1Hz,l H),4.18(dd,J=13.2,5.1Hz,l H),2.82(s,1H),1.54(s,3H).

[0102] Example 9: (S,E)-N-(4-amino-6-methyl-5-(quinolin-3-yl)-8,9-dihydropyrimidin[5,4-b]indolizin-8-yl)-4-(dimethylamino)-but-2-enamide

[0103]

[0104] The compound of Example 9 was synthesized by referring to the method of Example 8, wherein trans-4-dimethylaminocrotonic acid was used instead of propiolic acid to obtain the target compound (16.5 mg) as a light yellow solid. ESI-MS m / z: 454 [M+H] + .

[0105] 1 H-NMR (400 MHz, DMSO-d 6 ): δ8.92(s,l H),8.43(d,J=7.1Hz,lH),8.40(s,lH),8.12(s,lH),8.11(d,J=8.6Hz,lH),8.07(d,J=8.1Hz,lH),7.81(t,J=7.6Hz,l H),7.69(t,J=7.1Hz,l H),6.79-6.31(m,3H),6.03(s,2H),4.85-4.75(m,l H),4.28(dd,J=13.2,5.1Hz,l H),4.21(dd,J=13.2,5.1Hz,l H),3.08(d,J=7.6Hz,2H),2.76(s,6H)1.53(s,3H).

[0106] Comparative Example 1:

[0107] (S)-N-(4-amino-6-methyl-5-(quinolin-3-yl)-8,9-dihydropyrimido[5,4-b]indolizin-8-yl)acrylamide

[0108]

[0109] The compound was synthesized according to the method disclosed in International Patent WO 2015025936. ESI-MS m / z: 397 [M+H] + .

[0110] Example 10: Biological Activity Test

[0111] (1) Measurement of EGFR (T790M / L858R) kinase inhibitory activity

[0112] Among the materials for inhibitory activity measurement, substrate peptide and kinase protein were obtained as follows: Kinase protein was purchased from Carna Biosciences, Inc. as purified recombinant human EGFR (T790M / L858R) protein.

[0113] The inhibitory activity was measured as follows. (a) The test compound was prepared into a 10 mM stock solution in a EP tube with dimethyl sulfoxide solvent and stored in a -20°C refrigerator away from light until use. After the stock solution was diluted to the required concentration for the experiment, 250 nL was transferred to a 384-well plate using Echo550. Subsequently, a solution containing substrate peptide (final concentration: 250 nM), magnesium chloride (final concentration: 10 mM), manganese chloride (final concentration: 10 mM), and ATP (final concentration: 1 μM) in the buffer for kinase reaction was mixed with the dilutions of these compounds (final concentration of DMSO in kinase reaction: 2.5%). (b) A kinase buffer (1×Kinase buffer) was prepared and used to prepare a kinase solution with a final concentration of 2.5 times. (c) The prepared kinase solution was added to the compound wells and positive control wells, respectively, and the kinase sample volume was 10 μL; no kinase solution was added to the negative control wells, and 1×Kinase buffer was added to each well, with a volume of 10 μL. (d) Set the centrifuge speed to 1000 rpm and the time to 30 seconds. After centrifuge oscillation and mixing, place the 384-well plate at room temperature for incubation for 10 minutes. (e) Use 1×Kinase buffer to prepare a mixed solution of Kinase substrate 22 and ATP, and the final concentration of the solution is 25 / 15 times. Take 10μL of the mixed solution and transfer it to the 384-well plate to start the reaction. (f) Set the centrifuge speed to 1000 rpm and the time to 30 seconds. After centrifuge oscillation and mixing, place the 384-well plate at room temperature for incubation for 30 minutes. (g) Add the termination detection solution to the 384-well plate, add 30μL to each well to terminate the kinase reaction. (h) Set the centrifuge speed to 1000 rpm and the time to 30 seconds. After oscillation and mixing, use Caliper EZ Reader to determine the conversion rate of the sample. The calculation formula for the compound inhibition rate is:

[0114]

[0115] Finally, the obtained reaction inhibition rate (%) at each concentration was plotted against each compound, and the IC was determined using XLfit curve fitting software (IDBS). 50 Value (nM), which is the concentration of compound at which phosphorylation of EGFR (T790M / L858R) is inhibited by 50%.

[0116] (2) Measurement of EGFR (d746-750 / T790M) kinase inhibitory activity

[0117] The inhibitory activity of the compounds of the present invention against EGFR (d746-750 / T790M) kinase activity was measured.

[0118] The materials, measurement methods and data analysis methods were basically the same as those described above for "Measurement of EGFR (T790M / L858R) kinase inhibitory activity", except that purified recombinant human EGFR (d746-750 / T790M) protein was used as the kinase protein and a final ATP concentration of 1.5 μM was used for measurement. Finally, the IC values ​​of each compound for EGFR (d746-750 / T790M) were determined by data analysis. 50 Value (nM).

[0119] (3) Measurement of EGFR(L858R) kinase inhibitory activity

[0120] The inhibitory activity of the compounds of the present invention against EGFR (L858R) kinase activity was measured.

[0121] The materials, measurement methods and data analysis methods are substantially the same as those described above with respect to "Measurement of EGFR (T790M / L858R) kinase inhibitory activity", except that purified recombinant human EGFR (L858R) protein is used as the kinase protein and ATP is measured at a final concentration of 4 μM. Finally, the IC values ​​of each compound for EGFR (L858R) are determined by data analysis. 50 Value (nM).

[0122] (4) Measurement of EGFR (d746-750) kinase inhibitory activity

[0123] The inhibitory activity of the compounds of the present invention against EGFR (d746-750) kinase activity was measured.

[0124] The materials, measurement methods and data analysis methods are substantially the same as those described above with respect to "Measurement of EGFR (T790M / L858R) kinase inhibitory activity", except that purified recombinant human EGFR (d746-750) protein is used as the kinase protein, ATP is measured at a final concentration of 5 μM, and the incubation for the kinase reaction is performed for 90 minutes. Finally, the IC values ​​of each compound with respect to EGFR (d746-750) are determined by data analysis. 50 Value (nM).

[0125] (5) Measurement of EGFR (WT) kinase inhibitory activity

[0126] The inhibitory activity of the compounds of the present invention against EGFR (WT) kinase activity was measured.

[0127] The materials, measurement methods and data analysis methods were substantially the same as those described above with respect to “Measurement of EGFR (T790M / L858R) kinase inhibitory activity”, except that a kinase protein prepared by expressing the cytoplasmic domain of human EGFR (WT) fused to a FLAG tag at the N-terminus in insect Sf9 cells using a baculovirus expression system and then purifying it with anti-FLAG antibody agarose was used as the kinase protein, the final concentration of the substrate peptide was 500 nM, and the final concentration of ATP was 4.7 μM. Finally, the IC values ​​of each compound with respect to EGFR (WT) were determined by data analysis. 50 Value (nM).

[0128] Table 1 IC values ​​of the examples of the present invention and the reference compounds for activity determination 50 Data(nM)

[0129]

[0130]

[0131] The results showed that the compounds of the present invention exhibited good inhibitory activity against EGFR (T790M / L858R), EGFR (d746-750: / T790M), EGFR (L858R), and EGFR (d746-750), and had less inhibitory activity against EGFR (WT), achieving selective inhibition.

[0132] Example 11: Biological Activity Test

[0133] Test for growth inhibitory activity against cell lines expressing wild-type and mutant EGFR (in vitro). 1) Preparation of complete culture medium: Add 10 mL of fetal bovine serum to 89 mL of IMDM basal culture medium, and then add 1 mL of penicillin / streptomycin solution to prepare cell culture medium, and store in a 4°C refrigerator for use. 2) Preparation of test compounds: Accurately weigh the mass of the test compound using an analytical balance, add DMSO solution to prepare a 2 mg / mL mother solution, and store in a 4°C refrigerator for use. 3) The human non-small cell lung cancer cell line NCI-H1975 expressing EGFR (T790M / L858R), the human non-small cell lung cancer cell line HCC827 expressing EGFR (d746-750), and the human epithelial carcinoma cell line A431 expressing EGFR (WT) were each suspended in the complete growth medium recommended by ATCC, and after standing in an incubator (carbon dioxide 5%, temperature: 37°C) for 4 hours, the half-medium replacement method was used for passage, and the cell culture density was maintained at 1×10 5 ~1×10 6 cells mL -1 The cells were cultured at 37°C with 5% CO 2 4) Plating and adding drugs: Centrifuge the cells, remove the supernatant, add new culture medium, count with a counting plate, and count according to 1.5×10 5 cells mL -1 The inoculation density was inoculated in a 96-well plate. The test compound was diluted with culture medium to different concentrations, 9 concentrations, 3 parallels, and a blank control group (with cells and culture medium, no drug) and a positive control group (with cells and culture medium, with comparative example compound). Different concentrations of the test compound were added to the corresponding wells and incubated in an incubator for 72 hours. 5) Determination of OD value: 10 μL of CCK-8 solution was added to the blank well, positive control well and drug action well (drug group), and the incubation continued in CO 2 Incubate in an incubator for 4 hours. After shaking the plate (4 minutes), measure the OD value of each well at 450nm using an ELISA reader. 50 Calculation of GI values: GraphPad Prism 5 software was used to calculate the inhibition rate at different concentrations, and the inhibition rate curve was fitted into the corresponding function to calculate the GI value. 50 value.

[0134]

[0135] Among them, the OD value T of the drug group refers to the absorbance of the wells containing cells when the drug exposure time is T; the OD value T0 of the drug group refers to the absorbance of the wells containing cells when the drug exposure time is 0; the OD value T of the blank control group refers to the absorbance of the wells containing cells when the drug concentration is 0 and the exposure time is T; the OD value T0 of the blank control group refers to the absorbance of the wells containing cells when the drug concentration is 0 and the exposure time is 0.

[0136] Table 2 GI of the examples of the present invention and the reference compounds for activity determination 50 Data(nM)

[0137] EGFR Class EGFR(T790M / L858R) EGFR (d746-750) EGFR(WT) cell NCI-H1975 HCC827 A431 Example 1 53 13 1760 Example 2 61 17 1850 Example 3 42 10 1830 Example 4 125 31 1920 Example 5 130 42 2100 Example 6 45 12 1770 Example 7 132 38 2150 Example 8 56 17 1880 Example 9 37 11 1610 Comparative Example 1 83 21 1900

[0138] The results showed that the compounds of the present invention showed strong growth inhibitory effects not only on cells expressing EGFR (d746-750) but also on cells expressing EGFR (T790M / L858R); in addition, their growth inhibitory effects on cells expressing EGFR (WT) were lower than those on the above EGFR proteins.

[0139] Although the present invention has been described by the specific embodiments above, it should not be construed as being limited thereto; rather, the present invention encompasses the general aspects disclosed above. Various modifications and various embodiments are possible without departing from the spirit and scope of the present invention.

Claims

1. A compound having a structure represented by general formula (I) or a pharmaceutically acceptable salt thereof: Wherein, R1 is selected from: in, R2 is selected from H, D, F, Cl, Br; R3 and R4 are independently selected from H or D; and R2, R3, and R4 are not H at the same time.

2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, characterized in that: The compound is selected from:

3. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, characterized in that: The pharmaceutically acceptable salt is an inorganic salt or an organic salt. The inorganic salt is selected from hydrochloride, hydrobromide, hydroiodide, perchlorate, sulfate, bisulfate, nitrate, phosphate, and acid phosphate; the organic salt is selected from format, acetate, trifluoroacetate, propionate, pyruvate, glycolate, oxalate, malonate, succinate, glutarate, fumarate, maleate, lactate, malate, citrate, tartrate, methanesulfonate, ethanesulfonate, benzenesulfonate, salicylate, p-toluenesulfonate, and ascorbate.

4. A pharmaceutical composition comprising a compound of the structure represented by general formula (I) according to any one of claims 1 to 3 or a pharmaceutically acceptable salt thereof.

5. The pharmaceutical composition according to claim 4, characterized in that The pharmaceutical composition also includes: a pharmaceutically acceptable carrier, excipient or diluent.

6. The pharmaceutical composition according to claim 5, characterized in that The pharmaceutically acceptable carrier is selected from: microspheres, nanoparticles or liposomes.

7. The pharmaceutical composition according to claim 4, characterized in that The dosage form of the pharmaceutical composition is selected from the group consisting of tablets, pills, capsules, powders, granules, emulsions, suspensions, dispersions, solutions, tinctures, syrups, ointments, drops, suppositories, inhalants, sprays, and injections.

8. Use of a compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 3 in the preparation of a drug for treating a disease mediated by an activated EGFR or drug-resistant mutant in a mammal.

9. Use of the compound of the structure represented by general formula (I) according to any one of claims 1 to 3 or a pharmaceutically acceptable salt thereof in the preparation of anticancer drugs.

10. The use according to claim 9, characterized in that: The cancer is selected from the group consisting of lung cancer, breast cancer, kidney cancer, prostate cancer, pancreatic cancer, and epidermal cancer.